股本结构
单位：万股
| 公告日期 | 2026-10-20 | 2026-08-14 | 2026-08-14 | 2026-07-01 | 2026-05-29 | 2026-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1536.83 | 1536.83 | 1526.48 | 1522.83 | 1515.07 | 1016.26 |
| 普通股本 | 1536.83 | 1536.83 | 1526.48 | 1522.83 | 1515.07 | 1016.26 |
| 优先股 | 0.67 | 未披露 | 0.67 | 0.67 | 0.67 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-30 | 2026-08-12 | 2026-06-30 | 2026-06-29 | 2026-05-18 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-20 | 1536.83 | 0.67 | 定期报告 | 2026-09-30 |
| 2026-08-14 | 1536.83 | 未披露 | 定期报告 | 2026-08-12 |
| 2026-08-14 | 1526.48 | 0.67 |
更多>>
From March 31,2026 to June 30,2026
Issuance of common stock and warrants, net of offering costs
Shares issued for vested restricted stock units
|
2026-06-30 |
| 2026-07-01 | 1522.83 | 0.67 | 定期报告 | 2026-06-29 |
| 2026-05-29 | 1515.07 | 0.67 | 定期报告 | 2026-05-18 |
| 2026-04-30 | 1515.07 | 未披露 | 定期报告 | 2026-04-24 |
| 2026-04-15 | 1015.73 | 未披露 | 定期报告 | 2026-04-13 |
| 2026-05-15 | 1016.26 | 0.67 |
更多>>
From December 31,2025 to March 31,2026
Issuance of common stock, net of offering costs
Shares issued for vested restricted stock units
|
2026-03-31 |
| 2026-04-15 | 906.78 | 0.67 |
更多>>
From December 31, 2024 to December 31, 2025
Shares issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
Conversion of Series C Preferred shares into common stock
|
2025-12-31 |
| 2025-11-13 | 799.09 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-10-08 | 712.58 | 0.67 | 定期报告 | 2025-10-02 |
| 2025-11-13 | 713.12 | 0.67 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock, net of offering costs
|
2025-09-30 |
| 2025-08-14 | 706.38 | 未披露 | 定期报告 | 2025-08-12 |
| 2025-08-14 | 706.91 | 0.67 |
更多>>
From March 31, 2025 to June 30, 2025
Conversion of Series C Preferred shares
Stock issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
|
2025-06-30 |
| 2025-05-15 | 556.43 | 未披露 | 定期报告 | 2025-05-13 |
| 2025-04-30 | 533.40 | 未披露 | 定期报告 | 2025-04-28 |
| 2025-05-15 | 507.54 | 0.74 |
更多>>
From December 31, 2024 to March 31, 2025
Stock issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
|
2025-03-31 |
| 2025-03-31 | 507.38 | 未披露 | 定期报告 | 2025-03-26 |
| 2025-03-10 | 503.33 | 未披露 | 定期报告 | 2025-03-06 |
| 2025-03-10 | 311.86 | 未披露 | 定期报告 | 2025-02-06 |
| 2025-03-31 | 365.07 | 0.74 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of stock in connection with the asset acquisition of Trawsfynydd
Transaction costs paid through the issuance of stock
Issuance of stock in connection with the private placement, net of expenses
Conversion of redeemable convertible preferred stock upon stockholder approval
|
2024-12-31 |
| 2024-11-14 | 302.56 | 0.74 |
更多>>
From June 30, 2024 to September 30, 2024
Shares issued for vested restricted stock units
Conversion of redeemable convertible preferred stock upon stockholder approval
|
2024-09-30 |
| 2024-10-11 | 302.54 | 未披露 | 定期报告 | 2024-09-27 |
| 2024-09-17 | 182.66 | 未披露 |
更多>>
a reverse stock split ratio of one-for-twenty-five
|
2024-09-23 |
| 2024-09-17 | 4566.51 | 未披露 | 定期报告 | 2024-09-17 |
| 2024-08-09 | 2531.15 | 1.25 | 定期报告 | 2024-08-08 |
| 2024-08-15 | 2530.65 | 1.25 |
更多>>
From March 31, 2024 to June 30, 2024
Shares issued for vested restricted stock units
Transaction costs paid through the issuance of stock
Issuance of stock in connection with the asset acquisition of Trawsfynydd
Issuance of stock in connection with the private placement, net of expenses
|
2024-06-30 |
| 2024-07-01 | 2530.65 | 未披露 | 定期报告 | 2024-06-27 |
| 2024-04-04 | 2530.10 | 未披露 | 定期报告 | 2024-04-01 |
| 2024-05-15 | 2108.59 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Shares issued for vested restricted stock units
|
2024-03-31 |
| 2024-04-01 | 2104.06 | 未披露 | 定期报告 | 2024-03-01 |
| 2023-11-14 | 2100.34 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Shares issued for vested restricted stock units
|
2023-09-30 |
| 2023-06-30 | 2097.76 | 未披露 | 定期报告 | 2023-06-29 |
| 2023-06-06 | 2096.96 | 未披露 | 定期报告 | 2023-05-23 |
| 2023-05-15 | 2096.96 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-30 | 2096.96 | 未披露 | 定期报告 | 2023-03-01 |
| 2022-11-14 | 2092.60 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Shares issued for vested restricted stock units
|
2022-09-30 |
| 2022-03-21 | 2089.56 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
|
2021-12-31 |
| 2021-11-15 | 2089.06 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock, net
|
2021-09-30 |
| 2021-09-28 | 2078.10 | 未披露 |
更多>>
1.Common stock offered 5,000,000 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 15,781,040 shares of common stock outstanding as of June 30, 2021.
|
2021-09-28 |
| 2021-08-16 | 1578.10 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of stock options
Shares issued in connection with reverse stock split
|
2021-06-30 |
| 2021-05-28 | 1578.09 | 未披露 | 定期报告 | 2021-05-28 |
| 2021-05-20 | 1578.10 | 未披露 |
更多>>
The Reverse Stock Split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares. A copy of the Reverse Stock Split Certificate of Amendment is attached as Exhibit 3.1 hereto and is incorporated herein by reference.
|
2021-05-21 |
| 2021-05-17 | 23671.40 | 未披露 | 定期报告 | 2021-05-01 |
| 2021-05-17 | 23668.74 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Exercise of stock options
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
|
2021-03-31 |
| 2021-03-18 | 23661.24 | 未披露 | 定期报告 | 2021-02-28 |
| 2021-02-16 | 20954.83 | 未披露 |
更多>>
1.Common stock offered 25,000,000 shares by the company
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 184,548,267 shares of common stock outstanding as of September 30, 2020.
|
2021-02-16 |
| 2021-01-11 | 20669.44 | 未披露 |
更多>>
1.Common stock offered by the company 19,551,124 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 184,548,267 shares of common stock outstanding as of September 30, 2020.
|
2021-01-11 |
| 2021-01-08 | 18714.33 | 未披露 | 定期报告 | 2021-01-07 |
| 2021-03-18 | 18594.33 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock, net
Issuance of common stock upon exercise of common warrants
Issuance of common stock upon exercise of pre-funded warrants
|
2020-12-31 |
| 2020-11-16 | 18494.83 | 未披露 | 定期报告 | 2020-11-05 |
| 2020-11-16 | 18454.83 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of warrants
|
2020-09-30 |
| 2020-08-12 | 17965.36 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-08-12 | 17417.74 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of pre-funded warrants
|
2020-06-30 |
| 2020-05-15 | 16866.61 | 未披露 | 定期报告 | 2020-05-14 |
| 2020-05-15 | 16866.61 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-05-15 | 16741.61 | 未披露 |
更多>>
From December 31, 2019 to March 30, 2020
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
|
2020-03-30 |
| 2020-03-27 | 16725.61 | 未披露 | 定期报告 | 2020-03-01 |
| 2020-03-27 | 11116.74 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock, pre-funded warrants and warrants, net
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock upon exercise of common warrants
|
2019-12-31 |
| 2019-11-12 | 819.75 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock
|
2019-09-30 |
| 2019-09-25 | 819.75 | 未披露 | 定期报告 | 2019-09-25 |
| 2019-05-17 | 599.85 | 未披露 | 定期报告 | 2019-05-17 |
| 2019-05-15 | 589.50 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common stock upon exercise of warrants
|
2019-03-31 |
| 2019-04-01 | 589.50 | 未披露 | 定期报告 | 2019-03-01 |
| 2018-11-14 | 567.42 | 未披露 |
更多>>
From December 31, 2017 to September 30, 2018
Shares issued in connection with reverse stock split
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
|
2018-09-30 |
| 2018-09-26 | 567.00 | 未披露 |
更多>>
Onconova Therapeutics, Inc.(Nasdaq:ONTX) ("Onconova" or "the Company"), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer,with a primary focus on Myelodysplastic Syndromes (MDS), today announced a one-for-fifteen reverse stock split of its common stock, effective September 25, 2018.The reverse stock split will decrease the number of common shares issued and outstanding from approximately 85.11 million shares to approximately 5.67 million shares. The number of our authorized shares of common stock will remain at 250,000,000.
|
2018-09-26 |
| 2018-08-14 | 8511.18 | 未披露 |
更多>>
From December 31, 2017 to June 30, 2018
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
|
2018-06-30 |
| 2018-06-08 | 7910.78 | 未披露 | 定期报告 | 2018-05-25 |
| 2018-05-15 | 7760.78 | 未披露 | 定期报告 | 2018-05-07 |
| 2018-04-25 | 2024.31 | 未披露 | 定期报告 | 2018-04-20 |
| 2018-05-15 | 1942.62 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
|
2018-03-31 |
| 2018-03-16 | 1894.62 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-02-28 | 1852.62 | 未披露 | 定期报告 | 2018-02-16 |
| 2018-03-16 | 1077.12 | 未披露 |
更多>>
from December 31, 2016 to November 17, 2017
Issuance of common stock, net
|
2017-11-17 |
| 2017-11-09 | 985.12 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-09 | 985.12 | 未披露 |
更多>>
From December 31, 2016 to September 30, 2017
Issuance of common stock, net
|
2017-09-30 |
| 2017-08-14 | 985.12 | 未披露 | 定期报告 | 2017-07-31 |
| 2017-08-14 | 985.12 | 未披露 |
更多>>
From December 31, 2016 to June 30, 2017
Issuance of common stock, net
|
2017-06-30 |
| 2017-05-15 | 948.76 | 未披露 | 定期报告 | 2017-04-30 |
| 2017-05-15 | 677.27 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Issuance of common stock, net
|
2017-03-31 |
| 2017-04-12 | 677.27 | 未披露 | 定期报告 | 2017-03-01 |
| 2016-11-14 | 675.99 | 未披露 |
更多>>
from December 31, 2015 to September 30, 2016
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock, net
|
2016-09-30 |
| 2016-08-15 | 634.04 | 未披露 | 定期报告 | 2016-08-10 |
| 2016-08-15 | 274.06 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock, net
|
2016-06-30 |
| 2016-06-20 | 274.02 | 未披露 |
更多>>
All share and per share data has been restated to reflect one-for-ten reverse stock split effective May 31, 2016.
|
2016-06-01 |
| 2016-05-11 | 2740.10 | 未披露 |
更多>>
from December 31, 2015 to March 31, 2016
Issuance of common stock, net
|
2016-03-31 |
| 2016-03-28 | 2740.10 | 未披露 | 定期报告 | 2016-03-15 |
| 2016-03-28 | 2546.42 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common stock, net
Common stock surrendered
|
2015-12-31 |
| 2015-11-12 | 2486.84 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-10-20 | 2477.36 | 未披露 | 定期报告 | 2015-10-12 |
| 2015-08-13 | 2179.35 | 未披露 | 定期报告 | 2015-07-31 |
| 2014-08-14 | 2169.22 | 未披露 | 定期报告 | 2014-07-31 |
| 2014-05-15 | 2164.04 | 未披露 | 定期报告 | 2014-04-30 |
| 2014-04-29 | 2163.80 | 未披露 | 定期报告 | 2014-02-20 |
| 2013-09-06 | 260.95 | 1691.22 |
更多>>
from January 1, 2013 to July 17, 2013
Exercise of stock options
In connection with preparing for this offering, the Company's Board of Directors and stockholders approved a one-for-1.333 reverse stock split of the Company's Common Stock. The reverse stock split became effective on July 17, 2013.
|
2013-07-17 |
| 2013-06-14 | 347.85 | 1691.22 |
更多>>
from December 31, 2012 to March 31, 2013
Exercise of stock options
Accretion of preferred stock to redemption value
|
2013-03-31 |
From March 31,2026 to June 30,2026
Issuance of common stock and warrants, net of offering costs
Shares issued for vested restricted stock units
From December 31,2025 to March 31,2026
Issuance of common stock, net of offering costs
Shares issued for vested restricted stock units
From December 31, 2024 to December 31, 2025
Shares issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
Conversion of Series C Preferred shares into common stock
From June 30, 2025 to September 30, 2025
Issuance of common stock, net of offering costs
From March 31, 2025 to June 30, 2025
Conversion of Series C Preferred shares
Stock issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
From December 31, 2024 to March 31, 2025
Stock issued for vested restricted stock units
Issuance of common stock, net of offering costs
Exercise of prefunded warrants
From December 31, 2023 to December 31, 2024
Issuance of stock in connection with the asset acquisition of Trawsfynydd
Transaction costs paid through the issuance of stock
Issuance of stock in connection with the private placement, net of expenses
Conversion of redeemable convertible preferred stock upon stockholder approval
From June 30, 2024 to September 30, 2024
Shares issued for vested restricted stock units
Conversion of redeemable convertible preferred stock upon stockholder approval
a reverse stock split ratio of one-for-twenty-five
From March 31, 2024 to June 30, 2024
Shares issued for vested restricted stock units
Transaction costs paid through the issuance of stock
Issuance of stock in connection with the asset acquisition of Trawsfynydd
Issuance of stock in connection with the private placement, net of expenses
From December 31, 2023 to March 31, 2024
Shares issued for vested restricted stock units
From June 30, 2023 to September 30, 2023
Shares issued for vested restricted stock units
From June 30, 2022 to September 30, 2022
Shares issued for vested restricted stock units
From December 31, 2020 to December 31, 2021
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
From June 30, 2021 to September 30, 2021
Issuance of common stock, net
1.Common stock offered 5,000,000 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 15,781,040 shares of common stock outstanding as of June 30, 2021.
From March 31, 2021 to June 30, 2021
Exercise of stock options
Shares issued in connection with reverse stock split
The Reverse Stock Split will decrease the number of common shares issued and outstanding from approximately 236.714 million shares to approximately 15.781 million shares. A copy of the Reverse Stock Split Certificate of Amendment is attached as Exhibit 3.1 hereto and is incorporated herein by reference.
From December 31, 2020 To March 31, 2021
Exercise of stock options
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
1.Common stock offered 25,000,000 shares by the company
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 184,548,267 shares of common stock outstanding as of September 30, 2020.
1.Common stock offered by the company 19,551,124 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 184,548,267 shares of common stock outstanding as of September 30, 2020.
From December 31, 2019 to December 31, 2020
Issuance of common stock, net
Issuance of common stock upon exercise of common warrants
Issuance of common stock upon exercise of pre-funded warrants
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of warrants
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of pre-funded warrants
From December 31, 2019 to March 30, 2020
Issuance of common stock, net
Issuance of common stock upon exercise of warrants
From December 31, 2018 to December 31, 2019
Issuance of common stock, pre-funded warrants and warrants, net
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock upon exercise of common warrants
from June 30, 2019 to September 30, 2019
Issuance of common stock
From December 31, 2018 to March 31, 2019
Issuance of common stock upon exercise of warrants
From December 31, 2017 to September 30, 2018
Shares issued in connection with reverse stock split
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
Onconova Therapeutics, Inc.(Nasdaq:ONTX) ("Onconova" or "the Company"), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer,with a primary focus on Myelodysplastic Syndromes (MDS), today announced a one-for-fifteen reverse stock split of its common stock, effective September 25, 2018.The reverse stock split will decrease the number of common shares issued and outstanding from approximately 85.11 million shares to approximately 5.67 million shares. The number of our authorized shares of common stock will remain at 250,000,000.
From December 31, 2017 to June 30, 2018
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
From December 31, 2017 to March 31, 2018
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of warrants
from December 31, 2016 to November 17, 2017
Issuance of common stock, net
From December 31, 2016 to September 30, 2017
Issuance of common stock, net
From December 31, 2016 to June 30, 2017
Issuance of common stock, net
from December 31, 2016 to March 31, 2017
Issuance of common stock, net
from December 31, 2015 to September 30, 2016
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock and pre-funded warrants, net
Issuance of common stock upon exercise of pre-funded warrants
Issuance of common stock, net
from December 31, 2015 to June 30, 2016
Exercise of stock options
Shares issued in connection with reverse stock split
Issuance of common stock, net
All share and per share data has been restated to reflect one-for-ten reverse stock split effective May 31, 2016.
from December 31, 2015 to March 31, 2016
Issuance of common stock, net
from December 31, 2014 to December 31, 2015
Issuance of common stock, net
Common stock surrendered
from January 1, 2013 to July 17, 2013
Exercise of stock options
In connection with preparing for this offering, the Company's Board of Directors and stockholders approved a one-for-1.333 reverse stock split of the Company's Common Stock. The reverse stock split became effective on July 17, 2013.
from December 31, 2012 to March 31, 2013
Exercise of stock options
Accretion of preferred stock to redemption value